Guardant Health, Inc. (GH)

Akoya Biosciences Revenue by Segment

Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Precision Oncology Testing	687.94M	645.54M	598.36M	557.09M	514.25M	485.86M	454.49M	421.31M
Precision Oncology Testing Growth	33.77%	32.87%	31.66%	32.23%	31.17%	32.40%	32.05%	29.74%
Development Services	51.08M	46.72M	45.45M	46.64M	49.70M	49.93M	55.67M	60.85M
Development Services Growth	2.78%	-6.43%	-18.36%	-23.35%	-13.55%	-21.74%	-12.95%	-8.32%

Revenue by Geography

Period Ending	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Unitied States	781.99M	733.42M	697.16M	648.18M	603.81M	564.96M	526.52M	501.72M
Unitied States Growth	29.51%	29.82%	32.41%	29.19%	26.56%	25.92%	25.18%	23.95%
International	47.13M	40.84M	42.12M	44.07M	40.00M	38.76M	37.42M	34.06M
International Growth	17.83%	5.36%	12.56%	29.39%	20.93%	15.73%	29.41%	31.11%

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.